This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, Z. Articles by Iwase, H. Search for Related Content PubMed PubMed Citation Articles by Zhang, Z. Articles by Iwase, H.

HDAC6 Expression Is Correlated with Better Survival in Breast Cancer

¹ Department of Breast and Endocrine Surgery, Nagoya City University Hospital, Nagoya, Japan; ² Department of BioSciences, Karolinska Institute, NOVUM, Huddinge, Sweden; and ³ Division of Endocrinology, Saitama Cancer Center Research Institute, Saitama-ken, Japan

Purpose: The structure and function of chromatin can be altered by modifications to histone. Histone acetylation in vivo is a dynamic reversible process governed by histone acetyltransferases (HATs) and histone deacetylases (HDACs). HDAC6 is a unique isoform among the HDACs, and a gene expression pattern study, with cDNA microarray in MCF-7 cells, showed the HDAC6 gene to be late responsive, estrogen induced, and up-regulated. This led us to hypothesize that there was a link between levels of HDAC6 expression and the metastatic potential of breast cancer and also, therefore, the prognosis of these patients.

Experimental Design: In the present study, the level of HDAC6 mRNA expression was analyzed with quantitative real-time reverse transcription-PCR, in 135 female patients with invasive breast cancer. HDAC6 protein expression was also determined by immunohistochemistry. An association was sought between HDAC6 expression and various clinicopathologic factors.

Results: HDAC6 mRNA was expressed at significantly higher levels in breast cancer patients with small tumors measuring less than 2 cm, with low histologic grade, and in estrogen receptor - and progesterone receptor-positive tumors. By contrast, no relationship was found between HDAC6 mRNA expression and any of the other clinicopathologic factors, namely, age, menopausal status, and axillary lymph node involvement. Patients expressing high levels of HDAC6 mRNA and protein had a better prognosis than those expressing low levels, in terms of disease-free survival. However, multivariate analysis failed to show that HDAC6 mRNA and protein are an independent prognostic factors for disease-free survival and overall survival. Furthermore, the patients with high levels of HDAC6 mRNA tended to be more responsive to endocrine treatment than those with low levels. Specific HDAC6 staining was found in the nucleus of some normal epithelial cells and in the cytoplasm of the majority of cancer cells. Although postmenopausal patients showed higher HDAC6 protein expression, there were no relationship between protein expression and any other clinicopathologic factors.

Conclusions: We conclude that the levels of HDAC6 mRNA expression may have potential both as a marker of endocrine responsiveness and also as a prognostic indicator in breast cancer. Additional investigations are warranted concerning the relationship between HDAC6 expression and response to endocrine therapy.

This article has been cited by other articles:

				D. S. Schrump Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications Clin. Cancer Res., June 15, 2009; 15(12): 3947 - 3957. [Abstract] [Full Text] [PDF]

				L. Ellis, P. W. Atadja, and R. W. Johnstone Epigenetics in cancer: Targeting chromatin modifications Mol. Cancer Ther., June 1, 2009; 8(6): 1409 - 1420. [Abstract] [Full Text] [PDF]

				M. Haberland, A. Johnson, M. H. Mokalled, R. L. Montgomery, and E. N. Olson Genetic dissection of histone deacetylase requirement in tumor cells PNAS, May 12, 2009; 106(19): 7751 - 7755. [Abstract] [Full Text] [PDF]

				J. Suzuki, Y.-Y. Chen, G. K. Scott, S. DeVries, K. Chin, C. C. Benz, F. M. Waldman, and E. S. Hwang Protein Acetylation and Histone Deacetylase Expression Associated with Malignant Breast Cancer Progression Clin. Cancer Res., May 1, 2009; 15(9): 3163 - 3171. [Abstract] [Full Text] [PDF]

				V. Duong, C. Bret, L. Altucci, A. Mai, C. Duraffourd, J. Loubersac, P.-O. Harmand, S. Bonnet, S. Valente, T. Maudelonde, et al. Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells Mol. Cancer Res., December 1, 2008; 6(12): 1908 - 1919. [Abstract] [Full Text] [PDF]

				J. S. de Bono, R. Kristeleit, A. Tolcher, P. Fong, S. Pacey, V. Karavasilis, M. Mita, H. Shaw, P. Workman, S. Kaye, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors Clin. Cancer Res., October 15, 2008; 14(20): 6663 - 6673. [Abstract] [Full Text] [PDF]

				G. K. Scott, C. Marx, C. E. Berger, L. R. Saunders, E. Verdin, S. Schafer, M. Jung, and C. C. Benz Destabilization of ERBB2 Transcripts by Targeting 3' Untranslated Region Messenger RNA Associated HuR and Histone Deacetylase-6 Mol. Cancer Res., July 1, 2008; 6(7): 1250 - 1258. [Abstract] [Full Text] [PDF]

				K. Mita, Z. Zhang, Y. Ando, T. Toyama, M. Hamaguchi, S. Kobayashi, S.-i. Hayashi, Y. Fujii, H. Iwase, and H. Yamashita Prognostic Significance of Insulin-like Growth Factor Binding Protein (IGFBP)-4 and IGFBP-5 Expression in Breast Cancer Jpn. J. Clin. Oncol., August 3, 2007; (2007) hym066v1. [Abstract] [Full Text] [PDF]

				I. A. Kim, J. H. Shin, I. H. Kim, J. H. Kim, J. S. Kim, H. G. Wu, E. K. Chie, S. W. Ha, C. I. Park, and G. D. Kao Histone Deacetylase Inhibitor-Mediated Radiosensitization of Human Cancer Cells: Class Differences and the Potential Influence of p53 Clin. Cancer Res., February 1, 2006; 12(3): 940 - 949. [Abstract] [Full Text] [PDF]

				P. Bali, M. Pranpat, J. Bradner, M. Balasis, W. Fiskus, F. Guo, K. Rocha, S. Kumaraswamy, S. Boyapalle, P. Atadja, et al. Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90: A NOVEL BASIS FOR ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS J. Biol. Chem., July 22, 2005; 280(29): 26729 - 26734. [Abstract] [Full Text] [PDF]

				X.-J. Yang and S. Gregoire Class II Histone Deacetylases: from Sequence to Function, Regulation, and Clinical Implication Mol. Cell. Biol., April 15, 2005; 25(8): 2873 - 2884. [Full Text] [PDF]